Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07814352) titled 'A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Leptomeningeal Disease (LMD)
Intervention:
Drug: SX-682
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: September 4, 2026
Target Sample Size: 40
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.g...